Evidence map›Paper›PMID 20541521›Full record

ArticleArchives of biochemistry and biophysics2010

High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2.

Monalisa Swain, Mark G Slomiany, Steven A Rosenzweig, Hanudatta S Atreya

Abstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Monalisa SwainNMR Research Center, Indian Institute of Science, Bangalore 560012, India.
Mark G Slomiany
Steven A Rosenzweig
Hanudatta S Atreya
Indian Institute of Science Bangalore · INMedical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
Receptor Crosstalk in HNSCC Metastatic ProgressionR01CA134845 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROSENZWEIG, STEVEN ALAN · 2009 to 2016
$1.6M
INHIBITION OF IGF MEDIATED TUMORIGENESISR01CA078887 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROSENZWEIG, STEVEN A. · 2000 to 2004
$1.4M
Cancer Research UKNCI NIH HHS P30 CA138313NCI NIH HHS R01 CA078887NCI NIH HHS R01 CA134845NCI NIH HHS R01CA134845NCI NIH HHS R01CA78887
6 · The paper itself

Abstract

The diverse biological activities of the insulin-like growth factors (IGF-1 and IGF-2) are mediated by the IGF-1 receptor (IGF-1R). These actions are modulated by a family of six IGF-binding proteins (IGFBP-1-6; 22-31 kDa) that via high affinity binding to the IGFs (K(D) approximately 300-700 pM) both protect the IGFs in the circulation and attenuate IGF action by blocking their receptor access. In recent years, IGFBPs have been implicated in a variety of cancers. However, the structural basis of their interaction with IGFs and/or other proteins is not completely understood. A critical challenge in the structural characterization of full-length IGFBPs has been the difficulty in expressing these proteins at levels suitable for NMR/X-ray crystallography analysis. Here we describe the high-yield expression of full-length recombinant human IGFBP-2 (rhIGFBP-2) in Escherichia coli. Using a single step purification protocol, rhIGFBP-2 was obtained with >95% purity and structurally characterized using NMR spectroscopy. The protein was found to exist as a monomer at the high concentrations required for structural studies and to exist in a single conformation exhibiting a unique intra-molecular disulfide-bonding pattern. The protein retained full biologic activity. This study represents the first high-yield expression of wild-type recombinant human IGFBP-2 in E. coli and first structural characterization of a full-length IGFBP.

Indexed as

Base SequenceCell LineCircular DichroismDNA PrimersEscherichia coliHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor IIn Vitro TechniquesLigandsNuclear Magnetic Resonance, BiomolecularProtein ConformationRecombinant ProteinsThymidineDNA PrimersInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor ILigandsRecombinant ProteinsThymidine

Identifiers

PMID20541521
PMCPMC2934857
OpenAlexW2085844659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.